Table 1.

Baseline characteristics and empirical viral kinetic parameters

Patient No.	Age [yr]	GT	Fibrosis stage	SIL Dose	V0	ΔV0–1	ΔV1–2	ΔV0–2	s2–7	VK pattern*
25	48	1b	4	10	6.69	0.17	0.89	1.06	0.27	B
20	59	1a	4	10	6.95	0.18	0.11	0.26	0.17	M
28	56	1a	2	10	7.12	0.69	0.20	0.89	0.24	B
Mean (SD)	54				6.92 (0.22)	0.35 (0.30)	0.40 (0.43)	0.75 (0.42)	0.23 (0.05)
21	57	1b	3	15	6.65	0.44	0.03	0.41	0.15	B
22	49	4	0	15	5.95	0.67	0.73	1.40	0.36	B
29	58	1a	2	15	6.91	0.26	0.08	0.35	0.18	M
30	67	1a	2	15	5.75	0.65	0.25	0.90	0.65	M
36	41	1b	2	15	5.43	0.18	0.36	0.54	0.27	M
Mean (SD)	54				6.14 (0.62)	0.44 (0.22)	0.28 (0.28)	0.72 (0.44)	0.32 (0.20)
31	24	1b	2	20	6.44	1.07	1.25	2.31	0.27	B
32	33	1a	n.a.	20	6.98	1.15	1.04	2.19	0.50	B
33	48	1a	1	20	6.04	1.31	0.42	1.73	0.33	B
34	60	1b	4	20	6.50	0.57	0.39	0.96	0.18	B
35	49	1b	n.a.	20	6.68	1.52	1.14	2.66	0.40	B
26	60	1a	4	20	6.61	0.45	0.27	0.71	0.39	M
37	67	1b	1	20	6.07	0.50	0.31	0.81	0.34	M
38	68	1b	4	20	6.30	0.30	0.15	0.45	0.19	M
39	50	4	n.a.	20	5.77	0.39	0.65	1.04	0.27	B
40	69	1b	3	20	6.32	−0.32	0.53	0.21	0.19	M
41	50	1b	4	20	6.27	0.63	0.74	1.36	0.24	B
43	30	1b	2	20	5.65	0.59	0.41	1.00	0.26	B
44	55	1b	2	20	6.25	0.30	0.26	0.56	0.26	M
45	52	1a	2	20	7.66	0.30	0.75	1.06	0.35	M
46	68	4	n.a.	20	6.50	1.31	1.05	2.36	0.45	B
47	63	1	4	20	6.86	1.15	0.39	1.54	0.19	B
48	45	1a	n.a.	20	6.32	1.12	0.49	1.61	0.45	B
Mean (SD)	52				6.42 (0.47)	0.73 (0.49)	0.60 (0.34)	1.33 (0.73)	0.31 (0.10)
P-value&	0.93				0.64	0.09	0.03	0.04	0.29	0.67$

^*VK, viral kinetic pattern: B= biphasic and M=monophasic; s_i–j, HCV decline slope between days i and j (logIU/mL/day); ΔV_i–j, HCV decline between days i and j (logIU/mL); SIL dose (mg/kg/day); GT, HCV genotype; n.a., not available; V₀, baseline viral load (logIU/mL); SD, standard deviation;

^{& and $}P-value to reject the null hypothesis that the distribution between 10+15 and 20 SIL dosing groups is the same (Mann-Whitney test and Fisher’s exact test, respectively).